2024-06-17 13:20:51 ET
Summary
- Vertex Pharmaceuticals Incorporated is a $120bn market cap pharma giant with a successful CF franchise, growing revenues from $1bn in 2015 to $9.9bn in 2023.
- Vertex gained approval for its first non-CF drug, Casgevy, utilizing CRISPR technology to treat Sickle Cell disease and beta-thalassemia last year.
- Casgevy faces challenges with its launch due to the long treatment process, high costs, and lingering concerns over durability and safety.
- Nevertheless, this is a groundbreaking drug, and new, longer-term data shared by Vertex last week supports its strong efficacy profile - >95% of patients are free from transfusions/hospitalizations.
- This underlines the importance of Casgevy to Vertex. It's possible the therapy could generate double-digit billions in revenue for Vertex over the next decade.
Investment Overview - Vertex's Empire Built On CF Franchise - Casgevy First Non-CF Drug Approved
Vertex Pharmaceuticals Incorporated ( VRTX ) is a $120bn market cap (at the time of writing), Boston-based Pharma giant whose success is built upon its mighty cystic fibrosis ("CF") franchise - as per the company's latest quarterly report / Q1 2024 10-Q submission:
Our four approved CF medicines, led by TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), are being used to treat nearly three-quarters of the approximately 92,000 people with CF in North America, Europe, and Australia
Read the full article on Seeking Alpha
For further details see:
Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales